Physician Views snap-poll: Psychiatrists answer five key questions about Sage Therapeutics' Zulresso

Zulresso recently became the first specifically approved treatment for postpartum depression, which is estimated to affect as many as 400,000 new mothers each year in the US alone.

Administering Zulresso is not without its challenges, however, so we are snap-polling US psychiatrists to provide FirstWord Pharma PLUS readers additional insight on how this new therapy could impact the treatment landscape when it launches later this year. 

__________

Q. How would you characterise the overall level of unmet clinical need for women diagnosed with postpartum depression?

None

Low

Moderate

High

Very high

__________

Q. Zulresso (brexanolone) has become the first specifically approved treatment for postpartum depression in adult women. Approval is based on three pivotal trials showing that Zulresso provided a significant mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score at 60 hours compared to placebo. A reduction of depressive symptoms was also seen as early as 24 hours, and Zulresso maintained effect through the 30-day follow-up.

The most common adverse events in the studies were sleepiness, dry mouth, loss of consciousness and flushing. Zulresso can cause serious side effects, including excessive sedation and sudden loss of consciousness.

Taking into account efficacy and safety data, how compelling a therapy option do you think Zulresso is for the treatment of postpartum depression?

Not compelling

Slightly compelling

Moderately compelling

Very compelling

Extremely compelling

__________

Q. Zulresso requires administration by infusion over a 60-hour period at a certified facility capable of providing continuous patient monitoring. Patients then also require additional monitoring for 12 hours. Women receiving a Zulresso infusion will be required to have a caregiver or family member with them for childcare purposes.

To what extent do you think these requirements will limit adoption of Zulresso for the treatment of postpartum depression?

No impact

Slight impact

Moderate impact

Significant impact

Very significant impact 

__________

Q. Once Zulresso has become established in the marketplace, approximately what percentage of women diagnosed with postpartum depression would you expect to be treated with it?

__________

Q. If the FDA approved an oral treatment for postpartum depression offering comparable efficacy to Zulresso, how much more frequently would you expect this drug to be used?

Never

Infrequently

Sometimes

Often

All the time

__________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views Poll Results articles, click here.